# ✅ 

**Date**: 2026127 19:10  
**Status**: 📂 **！**

---

## 🎯 

### ✅ **** (`Submission_Package/`)
：Cover Letter +  + Figures + Tables

```
Submission_Package/
├── Manuscript_VHH_Humanization.md     ✅ （5500）
├── Cover_Letter.md                     ✅ 
├── README_SUBMISSION.md                ✅ 
├── Figures/                            ⏳ PNG
│   └── (Figure 1A/1B, Figure 2)
└── Tables/                             ✅ 
    ├── Table1_Clinical_Landscape.csv
    └── TableS1_Residue_Frequencies.csv
```

---

### ✅ **** (`Supplementary_Materials/`)
： +  + 

```
Supplementary_Materials/
├── README_SUPPLEMENTARY.md             ✅ 
├── Source_Data/                        ✅ 19VHH
│   └── Publication_Source_Data.csv
├── Sequences/                          ✅ 
│   ├── Reference_Germlines.fasta       ✅ （//）
│   ├── TheraSAbDab_19VHH_ANARCII_numbering_full.csv  ✅ IMGT
│   ├── TheraSAbDab_19VHH_FR_sequences.csv            ✅ FR
│   └── *.fasta                         ✅ Logo
└── Analysis_Reports/                   ✅ 
    ├── TheraSAbDab_19VHH_phylogeny_discrimination_analysis.txt  ✅
    ├── TheraSAbDab_19VHH_clustering_comparison.txt              ✅
    ├── TheraSAbDab_19VHH_New_Classification.txt                 ✅
    ├── *.newick                        ✅ 
    └── *_Vernier_Analysis.txt          ✅ 
```

---

## 📋 

### 1.  ✅
- ****: `Submission_Package/Manuscript_VHH_Humanization.md`
- ****: 
  - （250 words）
  - 10
  - Introduction（、）
  - 6Results（CDR3、Position 47、）
  - 6Discussion（Solubility Valve、）
  - 6Methods（、、）
  - 12
  - 

---

### 2.  ✅
**Table 1** (`Tables/Table1_Clinical_Landscape.csv`):
- 19VHH
- Columns: Name, Target, Phase, CDR3 Length, CDR2 Fold, Classification, Human Identity
- 4（Caplacizumab, Envafolimab, Ozoralizumab, Sonelokimab）

**Table S1** (`Tables/TableS1_Residue_Frequencies.csv`):
- Hallmark（FR2）：Pos 37, 44, 45, 47
- Vernier（FR1/FR2/FR3）：Pos 27-30, 48-49, 71, 93-94
- CDR3（Short ≤11 vs Long >11）

---

### 3.  ✅

**19VHH** (`Source_Data/Publication_Source_Data.csv`):
- 
- CDR3（5-21 aa）
- CDR2（H2-9-1, H2-10-1）
- （Human Identity %）
- （Camelid Identity %）
- （Class 1/2/3）

**** (`Sequences/Reference_Germlines.fasta`):
- Human IGHV3-23\*01
- Human IGHV3-13\*01
- Alpaca IGHV3-3\*01（VHH）
- Mouse IGHV1-72\*01
- ✅ **HallmarkVernier Zone**

**ANARCI** (`Sequences/TheraSAbDab_19VHH_ANARCII_numbering_full.csv`):
- IMGT
- FR1/FR2/FR3/FR4
- CDR1/CDR2/CDR3

**** (`Sequences/TheraSAbDab_19VHH_FR_sequences.csv`):
- 19VHHFR1/FR2/FR3/FR4
- /（%）

**Logo** (`Sequences/*.fasta`):
- FR1_Short_CDR3_lt11.fasta (N=5)
- FR1_Long_CDR3_ge11.fasta (N=14)
- FR2_Short_CDR3_lt11.fasta (N=5)
- FR2_long_CDR3_lt11.fasta (N=14) *[: typo]*
- FR3_Start_Long_CDR3_ge11.fasta
- WebLogo

---

### 4.  ✅

**Newick** (`Analysis_Reports/*.newick`):
- `TheraSAbDab_19VHH_FR2_anchored.newick` → FR2
- `TheraSAbDab_19VHH_FR3_anchored.newick` → FR3
- `TheraSAbDab_19VHH_FR2_FR3_anchored.newick` → FR2+FR3
- `Tree_FR2_Detailed.newick` → FR2
- `Tree_Combined_Detailed.newick` → 

**** (`phylogeny_discrimination_analysis.txt`):
- ✅ **FR2**: P=0.0251 (Strategy), ρ=-0.604, P=0.0062 (CDR3 length)
- ✅ **FR3**: （P>0.05）
- ✅ **FR2+FR3**: P=0.0106 (Strategy), ρ=-0.486, P=0.0350 (CDR3 length)

**** (`clustering_comparison.txt`):
- ✅ **FR2**: CDR3 Length P=0.00175 ✅✅, CDR2 Fold P=0.77 ❌
- ****: CDR3

**** (`New_Classification.txt`):
- ✅ **Class 1 (N=5)**: CDR3=9.0aa, Human 93.2%, Camelid 33.0%
- ✅ **Class 2 (N=10)**: CDR3=17.6aa, Human 87.9%, Camelid 32.7%
- ✅ **Class 3 (N=4)**: CDR3=15.2aa, Human 87.2%, Camelid 32.3%

---

### 5.  ✅

**Hallmark & Vernier** (`Hallmark_Vernier_Analysis_Corrected.txt`):
- ✅ **Position 47 (FR2)**:
  - Long CDR3: **Arg (R)** 13/14 (93%) → VHH-typical
  - Short CDR3: **Leu (L)/Pro (P)** 2/5 → Human-like
  
- ✅ **Position 71 (FR3)**:
  - **Arg (R)** 19/19 (100%) → Human IGHV3-23
  
**Vernier** (`Extended_Vernier_Analysis.txt`):
- ✅ **FR1 Vernier (27-30)**: Cys-Ala-Ala-Ser, 100%
- ✅ **FR3 Vernier (93-94)**: Tyr-Cys, 100%

**FR2 Vernier** (`FR2_Vernier_Analysis.txt`):
- ✅ **Pos 48-49**: Position 47
  - Long CDR3: Ala-Ala motif
  - Short CDR3: Ser-Gly/Ser motif

---

## 🔬 

### ✅ 

|  |  |  |
|---|---|---|
| P = 0.00175 | `clustering_comparison.txt` Line 8 | ✅ |
| ρ = -0.604, P = 0.0062 | `phylogeny_discrimination_analysis.txt` Line 22 | ✅ |
| Class 1: 93.2% | `New_Classification.txt` Line 6 | ✅ |
| Arg47: 13/14 (93%) | `Hallmark_Vernier_Analysis_Corrected.txt` Row 5 | ✅ |
| Arg71: 100% | Extended Vernier Analysis | ✅ |

****: ✅ **，**

---

### ✅ 

1. Hamers-Casterman, C., et al. (1993). *Nature*, 363, 446-448. ✅
2. Muyldermans, S. (2013). *Annu Rev Biochem*, 82, 775-797. ✅
3. Foote, J., & Winter, G. (1992). *JMB*, 224, 487-499. ✅
4. North, B., et al. (2011). *JMB*, 406, 228-256. ✅
5. Lefranc, M.P., et al. (2015). *NAR*, 43(D1), D413-D422. ✅
6. Dunbar, J., et al. (2014). *NAR*, 42(D1), D1140-D1146. ✅
7-12. Additional VHH engineering literature ✅

****: ✅ **，**

---

## 📁 

### ：
```
cd "d:\InSynBio-AI-Research\Antibody_Engineer_Suite\paper\Submission_Package"
```
****: Cover Letter +  + Figures + Tables

### ：
```
cd "d:\InSynBio-AI-Research\Antibody_Engineer_Suite\paper\Supplementary_Materials"
```
****:  +  + 

### ：
```
notepad "d:\InSynBio-AI-Research\Antibody_Engineer_Suite\paper\PAPER_ORGANIZATION_GUIDE.md"
```
****: 

---

## ⏳ 

### 🔴 HIGH PRIORITY：

**1. ** (15):
```powershell
cd "d:\InSynBio-AI-Research\Antibody_Engineer_Suite"
python scripts\visualize_phylogeny_detailed_11_inclusive.py
```
****: 
- TheraSAbDab_19VHH_FR2_detailed_11inclusive.png
- TheraSAbDab_19VHH_FR2_FR3_detailed_11inclusive.png

****: `Submission_Package\Figures\`

---

**2. Sequence Logo** (30):

****: FR2Logo
```bash
#  http://weblogo.threeplusone.com/ 
# WebLogo:
weblogo -f Sequences/FR2_Short_CDR3_lt11.fasta -o Figure2A_FR2_Short.png -F png --resolution 300
weblogo -f Sequences/FR2_long_CDR3_lt11.fasta -o Figure2B_FR2_Long.png -F png --resolution 300
```

---

### 🟡 MEDIUM PRIORITY：

**3. MarkdownDOCX** (10):
```powershell
cd "Submission_Package"
pandoc Manuscript_VHH_Humanization.md -o Manuscript_VHH_Humanization.docx
```

**4. ** (10):
- Cover Letter、、ORCID
- Author Contributions
- AcknowledgmentsFunding

**5. ** (10):
```powershell
cd "d:\InSynBio-AI-Research\Antibody_Engineer_Suite\paper"
Compress-Archive -Path "Supplementary_Materials\*" -DestinationPath "Supplementary_Data.zip"
```

---

## 🎉 

### ✅ （95%）
- ✅ 19VHH
- ✅ （Newick）
- ✅ （P、）
- ✅ Hallmark & Vernier Zone
- ✅ 
- ✅ （5500）
- ✅ 12
- ✅ （Table 1 + Table S1）
- ✅ 
- ✅ ANARCI
- ✅ （FASTA）
- ✅ Logo（FASTA）
- ✅ （ + ）
- ✅ README
- ✅ Cover Letter

### ⏳ （5%）
- ⏳ PNG（15）
- ⏳ Sequence Logo PNG（30）
- ⏳ MarkdownDOCX（10）
- ⏳ （10）

****: 1-1.5

---

## 🚀 

**Step 1**: 
```powershell
cd "d:\InSynBio-AI-Research\Antibody_Engineer_Suite"
python scripts\visualize_phylogeny_detailed_11_inclusive.py
```

**Step 2**: PNG
```powershell
dir *.png /s
```

**Step 3**: 
```powershell
Move-Item "TheraSAbDab_19VHH_FR2_detailed_11inclusive.png" "paper\Submission_Package\Figures\Figure1A_FR2_Phylogeny.png"
Move-Item "TheraSAbDab_19VHH_FR2_FR3_detailed_11inclusive.png" "paper\Submission_Package\Figures\Figure1B_FR2FR3_Phylogeny.png"
```

****: 100%！🎊

---

## 📧 

，：
- ****: `Submission_Package/README_SUBMISSION.md`
- ****: `Supplementary_Materials/README_SUPPLEMENTARY.md`
- ****: `PAPER_ORGANIZATION_GUIDE.md`
- **MDPI**: antibodies@mdpi.com

---

**！**

、、。  
、、。  
，！🚀

---

****: 2026127 19:10  
****: 📂 **100%，**
